Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol PR in Chronic Malignant Tumor-related Pain
NCT01264887Phase 3Terminated
- Sponsor
- Grünenthal GmbH
- Start
- Mar 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of tapentadol in cancer pain, sponsored by Grünenthal GmbH. Primary endpoints: Severity of Adverse Events up to 144 weeks, Relatedness Assessment of Treatment Emergent Adverse Events up to 144 weeks and 2 more. Started Mar 2011; status: terminated.
02
Drugs
tapentadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01264887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264887.